Ocrevus Archives -

Roche Q3 results show steep fall-off in COVID product sales

Phil Taylor COVID-19, Evrysdi, Financial, Hemlibra, Ocrevus, Phesgo, Roche, Vabysmo 0 Comment

Roche’s third-quarter results have revealed a clear sign that the bumper sales boosting companies that have provided products

Roche Q3 results show steep fall-off in COVID product sales

https://pharmaphorum.com/news/roche-q3-results-show-steep-fall-off-in-covid-product-sales/

Market Access/ News/ News

NICE says yes to Novartis’ multiple sclerosis therapy Kesimpta

Phil Taylor HEOR, Kesimpta, multiple sclerosis, neurology, NHS, NICE, Novartis, Ocrevus, Roche 0 Comment

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just

NICE says yes to Novartis’ multiple sclerosis therapy Kesimpta

https://pharmaphorum.com/news/nice-says-yes-to-novartis-multiple-sclerosis-therapy-kesimpta/

News/ News/ Sales and Marketing/ Top stories

Roche hits back at Novartis with new data for MS drug Ocrevus

Richard Staines multiple sclerosis, Novartis, Ocrevus, Roche 0 Comment

Roche has hit back at Novartis’ newly-approved multiple sclerosis drug Kesimpta, with new data from its already-marketed blockbuster

Roche hits back at Novartis with new data for MS drug Ocrevus

https://pharmaphorum.com/news/roche-hits-back-at-novartis-with-new-data-for-ms-drug-ocrevus/

Market Access/ News/ News

US, EU reviews start for Novartis’ Ocrevus rival ofatumumab

Phil Taylor CNS, multiple sclerosis, Novartis, Ocrevus, Roche 0 Comment

Novartis’ cancer therapy ofatumumab has moved closer to its second life as a treatment for multiple sclerosis, with

US, EU reviews start for Novartis’ Ocrevus rival ofatumumab

https://pharmaphorum.com/news/us-eu-reviews-start-for-novartis-ocrevus-rival-ofatumumab/

News/ News/ Sales and Marketing

Roche raises 2019 outlook, shrugging off biosimilar threat

Phil Taylor Avastin, biosimilar, Hemlibra, herceptin, Ocrevus, Rituxan, Roche, Tecentriq 0 Comment

New product sales helped Roche to a healthy 9% increase in sales in the first half of the

Roche raises 2019 outlook, shrugging off biosimilar threat

https://pharmaphorum.com/news/roche-raises-2019-outlook-shrugging-off-biosimilar-threat/

Patients/ Views & Analysis/ Views and analysis

Addressing MS’ two-tier healthcare system is about ‘social justice’

Amanda Barrell MS, MS Trust, multiple sclerosis, Ocrevus 0 Comment

NICE has reversed its decision not to approve a new drug that offers hope to thousands of people

Addressing MS’ two-tier healthcare system is about ‘social justice’

https://pharmaphorum.com/views-analysis-patients/ms-two-tier-healthcare-system/

News/ News/ R&D/ Roche/ Top stories

Roche’s MS drug Ocrevus earns blockbuster status a year after launch

Joy Persaud multiple sclerosis, Ocrevus, Roche 0 Comment

Roche’s multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has claimed blockbuster status just one year after it was launched.

Roche’s MS drug Ocrevus earns blockbuster status a year after launch

https://pharmaphorum.com/news/roche-ms-ocrevus-blockbuster/

Market Access/ News/ News/ Pharma Market Access/ UK & Europe

Roche’s MS drug Ocrevus nears European market

Andrew McConaghie multiple sclerosis, Ocrevus 0 Comment

Roche’s new multiple sclerosis drug Ocrevus (ocrelizumab) gained FDA approval in March, and since then has achieved remarkable

Roche’s MS drug Ocrevus nears European market

https://pharmaphorum.com/news/roches-multiple-sclerosis-drug-ocrevus-heading-european-market-received-backing-regulators/

News/ Roche

Brain infection would be bad news for Roche’s MS drug Ocrevus

Richard Staines multiple sclerosis, neurology, Novartis, Ocrevus, Roche, safety 0 Comment

Suggestion is that PML case was caused by previous treatment.

Brain infection would be bad news for Roche’s MS drug Ocrevus

https://pharmaphorum.com/news/roche-investigates-ocrevus/

Trending

Ocrevus

Login